Similarly, the NOX2-specific inhibitor GSK2795039 has been used to investigate its role in atherosclerosis, revealing that ROS generated by NOX2 affects macrophage phagocytic function and the stability of vulnerable plaques [46]. Here, CYBB is linked to atherosclerosis.